XML 101 R89.htm IDEA: XBRL DOCUMENT v3.23.1

Litigation (Drug Pricing Matters) (Details)	Aug. 30, 2021	Mar. 31, 2023	Mar. 31, 2023 state
Ocular AS
Loss Contingencies [Line Items]
Loss Contingency, Damages Sought	155 million
Multi District Litigation [Member]
Loss Contingencies [Line Items]
Number of states		46	46
Anticompetitive Conduct with Doxycycline Hyclate Delayed Release, Doxycycline Monohydrate, Glipizide-Metformin and Verapamil [Member]
Loss Contingencies [Line Items]
Number of states		36
Anticompetitive Conduct with Generic Drugs [Member]
Loss Contingencies [Line Items]
Number of states		47
Amended Anticompetitive Conduct with Generic Drugs [Member]
Loss Contingencies [Line Items]
Number of states		42

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482425/460-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483076/450-20-50-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483076/450-20-50-4

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483076/450-20-50-4

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483076/450-20-50-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483076/450-20-50-9

+ Details

Name:	us-gaap_LossContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Describes the form and magnitude of the award the plaintiff seeks in the legal matter, which may include an unspecified amount of money.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483076/450-20-50-4

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483076/450-20-50-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483076/450-20-50-9

+ Details

Name:	us-gaap_LossContingencyDamagesSought
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of states

+ References

No definition available.

+ Details

Name:	vtrs_Numberofstates
Namespace Prefix:	vtrs_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

X

- Details

Name:	srt_CounterpartyNameAxis=vtrs_OcularASMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_LitigationCaseAxis=vtrs_MultiDistrictLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_LitigationCaseAxis=vtrs_AnticompetitiveConductwithDoxycyclineHyclateDelayedReleaseDoxycyclineMonohydrateGlipizideMetforminandVerapamilMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_LitigationCaseAxis=vtrs_AnticompetitiveConductwithGenericDrugsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_LitigationCaseAxis=vtrs_AmendedAnticompetitiveConductwithGenericDrugsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: